
AVTECH - Clear path for continued growth

Redeye states that the report aligned with preliminary figures and showed net sales in line with estimates, but EBITDA was slightly below Redeye's expectations. The EBITDA 'miss' is related to 'elevated' OPEX, which we expect to remain as AVTECH plans on significant investments during 2024 to expand its product portfolio. Redeye sees short-term catalysts as it expects a few legacy carriers to conclude trials during Q1 2024. Redeye raised its fair value range.

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

[AVTECH - Clear path for continued growth](#)